查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679376

阿茲海默症診斷市場規模、佔有率、趨勢分析報告：按診斷技術、類型、最終用途、地區和細分市場預測，2025-2030 年

Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostics Technique (Biomarkers, Imaging Techniques, Genetic Testing), By Type (Triage, Diagnosis, Screening), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

阿茲海默症診斷市場的成長和趨勢

根據Grand View Research, Inc.的新報告，全球阿茲海默症診斷市場預計到2030年將達到155.7億美元。

預計 2025 年至 2030 年間，市場複合年成長率將達到 11.03%。阿茲海默症(AD) 盛行率上升、生物標記在疾病診斷中的使用增加、個人化產品的採用日益增多以及醫學影像技術的不斷進步是預計推動阿茲海默症診斷需求的一些因素。政府投資和研發投入的增加正在進一步刺激成長。

全球人口老化以及患有阿茲海默症慢性疾病（最常見的失智症）也是推動阿茲海默症診斷市場發展的主要因素。根據世界衛生組織統計，阿茲海默症佔所有失智症的60%至70%，是最常見的失智症。根據阿茲海默症協會報告，預計到2023年，670萬65歲以上的美國人將罹患阿茲海默症。預計到 2060 年，這一數字將成長近兩倍，達到 1,380 萬人，而美國阿茲海默症的醫療費用預計到 2022 年將達到約 3,210 億美元。

市場趨勢正在轉向開發更準確、非侵入性的診斷工具。最近的技術發展導致了可以在腦脊髓液和血液樣本中檢測到的生物標記（例如澱粉樣BETA蛋白和Tau蛋白）的開發。這些生物標記有望早期發現阿茲海默症，從而實現早期干預和治療。此外，功能性磁振造影（fMRI）和正子斷層掃描（PET）等神經影像技術的進步提高了診斷阿茲海默症的準確性。

阿茲海默症創新診斷技術的最新進展包括開發基於血液的生物標記物，例如 p-tau217 測試。另一個例子是使用數位生物標記（如認知評估和穿戴式裝置）來追蹤認知能力下降並識別阿茲海默症的早期跡象。 Biogen 和Eisai等公司也正在投資數位健康技術，以支持臨床測試並改善患者的治療效果。此外，研究人員正在探索機器學習和自然語言處理的潛力，以分析語音模式並識別認知能力下降的早期徵兆。診斷技術的這些進步有望徹底改變阿茲海默症的診斷領域，實現早期療育和更有效的治療策略。

政府資助計畫旨在資助各種臨床試驗，以減輕整形外科疾病的負擔，預計將對市場產生積極影響。該資金用於支持新診斷技術的開發，包括先進的成像技術、生物標記檢測法和認知評估工具。增加研發投入將有助於加快創新步伐並將新的診斷解決方案推向市場。

市場的主要企業包括 Quest Diagnostics、Labcorp、C2N Diagnostics、 FUJIREBIO、Bristol Myers Squibb、Hoffmann-La Roche 和 Quanterix。這些公司正在採取各種策略性舉措，包括產品發布和核准，以服務其全球客戶。例如，2024 年 4 月，Quest Diagnostics 宣布擴大其產品組合，增加針對磷酸化Tau 217（p-tau217）的新型血液生物標記測試。此外，兩家公司還在一系列基於血液的生物標記、腦脊髓液測試和基因測試方面進行創新，以提供全面的大腦健康產品。

阿茲海默症診斷市場報告重點

  • 按診斷技術分類，成像技術將在 2024 年佔據最大的收益佔有率。預計此類舉措將推動市場成長。如此高的比例是由於迫切需要早期和準確地檢測這種疾病。電腦斷層掃描 (CT)、正子斷層掃描 (PET) 和功能性磁振造影 (fMRI) 等影像技術的進步已成為診斷和監測疾病的重要工具。
  • 從類型來看，診斷產品佔據了市場主導地位，在2024年佔據了最大的佔有率。隨著社會老化，罹患阿茲海默症風險的人數不斷增加，全球市場也不斷擴大。這增加了對早期和準確診斷工具的需求，從而推動了市場的發展。
  • 根據最終用途，學術和研究機構在 2024 年佔據了最大的市場佔有率。這是由於過去十年對神經系統疾病的研究和臨床測試增加。學術和研究機構處於先進研究、臨床測試和創新診斷技術開發的前沿。
  • 北美在全球市場佔據主導地位，因為北美擁有許多處於阿茲海默症生物標記研究前沿的關鍵市場參與企業，包括腦脊髓液分析和血液生物標記。這些進步正在促進更準確、侵入性更小的診斷測試的發展。
  • 預計亞太地區將在 2025-2030 年預測期內出現最快的成長。這是由於擁有創新設備製造能力的製造商的存在以及診斷研究的加速。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章阿茲海默症診斷市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 阿茲海默症診斷市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析
  • 阿茲海默症診斷市場：使用案例分析

第4章阿茲海默症診斷市場：診斷技術的估計和趨勢分析

  • 2024 年和 2030 年診斷市場佔有率
  • 細分儀表板
  • 阿茲海默症診斷市場：診斷技術變革分析
  • 阿茲海默症診斷市場的全球展望（按診斷技術）
  • 生物標記
    • 腦脊髓液生物標記
    • 血液中的生物標記
  • 成像技術
  • 基因檢測
  • 認知評估測試

第5章阿茲海默症診斷市場：按類型估計和趨勢分析

  • 2024年和2030年的類型市場佔有率
  • 細分儀表板
  • 全球阿茲海默症診斷市場（按類型）展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 分類
  • 診斷
  • 篩檢

第6章阿茲海默症診斷市場：按最終用途的估計和趨勢分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • 全球阿茲海默症診斷市場（依最終用途）展望
  • 2018-2030 年市場規模、預測及趨勢分析
  • 醫院
  • 診斷實驗室
  • 學術研究所

第7章阿茲海默症診斷市場：區域、估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 市場規模、預測趨勢分析，2018-2030
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT 分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT 分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT 分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 2024年主要企業市場佔有率分析
    • Quest Diagnostics Incorporated
    • Laboratory Corporation of America Holdings
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • C2N diagnostics
    • FujireBio
    • Bristol Myers Squibb Company
    • Quanterix
    • Sysmex
    • Lantheus
Product Code: GVR-4-68040-323-7

Alzheimer's Disease Diagnostics Market Growth & Trends:

The global Alzheimer's disease diagnostics market size is anticipated to reach USD 15.57 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 11.03% from 2025 to 2030. The market is driven by rising prevalence of Alzheimer's disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging are some of the factors which is expected to drive the demand for Alzheimer's disease diagnostics. Increasing government investments and R&D studies is further propelling growth.

The global aging population with chronic conditions such as Alzheimer's disease, which is the most common form of dementia, is another major factor driving the market for Alzheimer's disease diagnostics. According to the WHO, Alzheimer's disease causes 60-70% of all instances of dementia, making it the most common kind. According to the Alzheimer's Association reports, an estimated 6.7 million Americans aged 65 and older were living with Alzheimer's disease in 2023. This number is projected to nearly triple to 13.8 million people by 2060, and the studies project that the healthcare cost for AD patients in 2022 was around USD 321 billion in the U.S, itself.

The market trends are shifting towards the development of more accurate and non-invasive diagnostic tools. Recent advances in technology have led to the development of biomarkers, such as amyloid-beta and tau proteins, which can be detected in cerebrospinal fluid or blood samples. These biomarkers have shown promise in detecting Alzheimer's disease in its early stages, allowing for earlier intervention and treatment. Additionally, advances in neuroimaging techniques, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), have improved the accuracy of Alzheimer's disease diagnosis.

Recent examples of innovative diagnostic technologies for Alzheimer's disease include the development of blood-based biomarkers, such as the p-tau217 test, which has shown high accuracy in detecting the disease. Another example is the use of digital biomarkers, such as cognitive assessments and wearable devices, to track cognitive decline and identify early signs of Alzheimer's disease. Companies such as Biogen and Eisai are also investing in digital health technologies to support clinical trials and improve patient outcomes. Moreover, researchers are exploring the potential of machine learning and natural language processing to analyze speech patterns and identify early signs of cognitive decline. These advances in diagnostic technology are expected to revolutionize the field of Alzheimer's disease diagnosis, enabling earlier intervention and more effective treatment strategies.

Presence of government funding programs aimed at reducing the burden of orthopedic diseases, by funding various clinical trials aimed at, is expected to have a positive impact on the market, In addition, governments are allocating substantial funds for research and development (R&D) in the field of Alzheimer's diagnostics. This funding supports the development of new diagnostic technologies, such as advanced imaging techniques, biomarker assays, and cognitive assessment tools. Increased R&D investment accelerates the pace of innovation and helps bring new diagnostic solutions to the market

Some of the key players in the market are Quest Diagnostics, Labcorp, C2N Diagnostics, Fujirebio, Bristol Myers Squibb, Hoffmann-La Roche, and Quanterix. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in April 2024, Quest Diagnostics announced its portfolio expansion by adding a new blood biomarker test for phosphorylated tau 217 (p-tau217). Companies further have been innovating in various blood-based biomarkers, cerebrospinal fluid tests, and genetic tests to provide a comprehensive offering in brain health.

Alzheimer's Disease Diagnostics Market Report Highlights:

  • Based on diagnostics technique, imaging techniques accounted for the largest revenue share in 2024. Such initiatives are expected to drive market growth. This high share is attributable to the urgent need for early and accurate detection of the disease. Advancements in imaging technologies such as Computed Tomography (CT), Positron Emission Tomography (PET), functional MRI (fMRI) have emerged as crucial tools for diagnosing and monitoring the disease.
  • Based on type, diagnosis dominated the market and accounted for the largest share in 2024. The global market is expanding as the aging population rises, with more individuals at risk of developing Alzheimer's disease. This has heightened the demand for early and accurate diagnostic tools, driving the market forward.
  • Based on end use, academic and research institutes segment dominated the market with the largest market share in 2024. This is attributable to the increase in the research studies and clinical trials for neurological disorders over the last decade. Academic and research institutes are at the forefront of advanced research, clinical trials, and the development of innovative diagnostic techniques.
  • North America dominated the global market due to the presence of a large number of major market players at the forefront of research into Alzheimer's disease biomarkers, including cerebrospinal fluid analysis and blood-based biomarkers. These advancements are driving the development of more accurate and minimally invasive diagnostic tests.
  • The Asia Pacific region is expected to witness the fastest growth over the forecast period from 2025 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Diagnostics Technique
    • 1.2.2. Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Diagnostics Technique outlook
    • 2.2.2. Type outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Alzheimer's Disease Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of Alzheimer's disease
      • 3.2.1.2. Increasing use of biomarkers in diagnosis
      • 3.2.1.3. Growing adoption of personalized products
      • 3.2.1.4. Growing R&D studies and government investments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations
  • 3.3. Alzheimer's Disease Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
  • 3.4. Alzheimer's Disease Diagnostics Market: Case Study Analysis

Chapter 4. Alzheimer's Disease Diagnostics Market: Diagnostics Technique Estimates & Trend Analysis

  • 4.1. Diagnostics Techniques Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Alzheimer's Disease Diagnostics Market: Diagnostics Technique Movement Analysis
  • 4.4. Alzheimer's Disease Diagnostics Market Size & Trend Analysis, by diagnostic technique, 2018 to 2030 (USD Million)
  • 4.5. Biomarker
    • 4.5.1. Biomarker Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. CSF Biomarkers
      • 4.5.2.1. CSF Biomarkers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Blood Based Biomarker
      • 4.5.3.1. Blood Based Biomarker Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Imaging Techniques
    • 4.6.1. Imaging Techniques Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Genetic Testing
    • 4.7.1. Genetic Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Cognitive Assessment Tests
    • 4.8.1. Cognitive Assessment Tests Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Alzheimer's Disease Diagnostics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Alzheimer's Disease Diagnostics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Triage
    • 5.5.1. Triage Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Diagnosis
    • 5.6.1. Diagnosis Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Screening
    • 5.7.1. Screening Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Alzheimer's Disease Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Alzheimer's Disease Diagnostics Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Academic and Research Institutes
    • 6.7.1. Academic and Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Alzheimer's Disease Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. North America: SWOT Analysis
    • 7.5.2. U.S.
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/Reimbursement
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Canada
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/Reimbursement
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/Reimbursement
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. Europe: SWOT Analysis
    • 7.6.2. UK
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/Reimbursement
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Germany
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/Reimbursement
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. France
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/Reimbursement
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Italy
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/Reimbursement
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Spain
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/Reimbursement
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Norway
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/Reimbursement
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Sweden
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/Reimbursement
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.9. Denmark
      • 7.6.9.1. Key country dynamics
      • 7.6.9.2. Regulatory framework/Reimbursement
      • 7.6.9.3. Competitive scenario
      • 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Asia Pacific: SWOT Analysis
    • 7.7.2. Japan
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/Reimbursement
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. China
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/Reimbursement
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. India
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/Reimbursement
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Australia
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/Reimbursement
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. South Korea
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/Reimbursement
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.7. Thailand
      • 7.7.7.1. Key country dynamics
      • 7.7.7.2. Regulatory framework/Reimbursement
      • 7.7.7.3. Competitive scenario
      • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Latin America: SWOT Analysis
    • 7.8.2. Brazil
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/Reimbursement
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/Reimbursement
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. MEA: SWOT Analysis
    • 7.9.2. South Africa
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/Reimbursement
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. Saudi Arabia
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/Reimbursement
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. UAE
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/Reimbursement
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.5. Kuwait
      • 7.9.5.1. Key country dynamics
      • 7.9.5.2. Regulatory framework
      • 7.9.5.3. Competitive scenario
      • 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Quest Diagnostics Incorporated
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Services benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Laboratory Corporation of America Holdings
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Services benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. F. Hoffmann-La Roche Ltd.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Services benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Siemens Healthineers AG
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Services benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. C2N diagnostics
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Services benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. FujireBio
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Services benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Bristol Myers Squibb Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Services benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Quanterix
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Services benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Sysmex
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Services benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Lantheus
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Services benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Alzheimer's disease diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 4 North America Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 7 U.S. Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Canada Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 10 Canada Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 Mexico Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 13 Mexico Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 14 Mexico Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 Europe Alzheimer's disease diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 17 Europe Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 18 Europe Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Germany Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 20 Germany Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 21 Germany Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 UK Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 23 UK Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 24 UK Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 France Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 26 France Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 27 France Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Italy Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 29 Italy Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 30 Italy Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Spain Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 32 Spain Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 33 Spain Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Denmark Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 35 Denmark Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Sweden Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 38 Sweden Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Norway Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 41 Norway Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 42 Norway Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Alzheimer's disease diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 China Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 48 China Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 49 China Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Japan Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 51 Japan Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 52 Japan Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 India Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 54 India Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 55 India Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 South Korea Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 57 South Korea Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Australia Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 60 Australia Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 61 Australia Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Thailand Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 63 Thailand Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Latin America Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 66 Latin America Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 68 Brazil Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 69 Brazil Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 70 Brazil Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Argentina Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 72 Argentina Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 MEA Alzheimer's disease diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 76 MEA Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 77 MEA Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 78 South Africa Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 79 South Africa Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 UAE Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 85 UAE Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)
  • Table 86 UAE Alzheimer's disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 87 Kuwait Alzheimer's disease diagnostics market, by diagnostics technique, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Alzheimer's disease diagnostics market, by type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Alzheimer's disease diagnostics market: market outlook
  • Fig. 14 Alzheimer's disease diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Alzheimer's disease diagnostics market driver impact
  • Fig. 20 Alzheimer's disease diagnostics market restraint impact
  • Fig. 21 Alzheimer's disease diagnostics market strategic initiatives analysis
  • Fig. 22 Alzheimer's disease diagnostics market: Diagnostics technique movement analysis
  • Fig. 23 Alzheimer's disease diagnostics market: Diagnostics technique outlook and key takeaways
  • Fig. 24 Biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 25 CSF biomarkers estimates and forecast, 2018 - 2030
  • Fig. 26 Blood based biomarkers market estimates and forecast, 2018 - 2030
  • Fig. 27 Imaging techniques estimates and forecast, 2018 - 2030
  • Fig. 28 Genetic testing market estimates and forecast, 2018 - 2030
  • Fig. 29 Cognitive assessment tests market estimates and forecasts,2018 - 2030
  • Fig. 30 Alzheimer's disease diagnostics Market: Test type movement analysis
  • Fig. 31 Alzheimer's disease diagnostics market: Test type outlook and key takeaways
  • Fig. 32 Triage market estimates and forecasts, 2018 - 2030
  • Fig. 33 Diagnosis market estimates and forecasts, 2018 - 2030
  • Fig. 34 Screening market estimates and forecasts, 2018 - 2030
  • Fig. 35 Alzheimer's disease diagnostics market: End-use movement analysis
  • Fig. 36 Alzheimer's disease diagnostics market: End-use outlook and key takeaways
  • Fig. 37 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 38 Diagnostic laboratories market estimates and forecasts, 2018 - 2030
  • Fig. 39 Academic and research institutes market estimates and forecasts, 2018 - 2030
  • Fig. 40 Global Alzheimer's disease diagnostics market: Regional movement analysis
  • Fig. 41 Global Alzheimer's disease diagnostics market: Regional outlook and key takeaways
  • Fig. 42 Global Alzheimer's disease diagnostics market share and leading players
  • Fig. 43 North America market share and leading players
  • Fig. 44 Europe market share and leading players
  • Fig. 45 Asia Pacific market share and leading players
  • Fig. 46 Latin America market share and leading players
  • Fig. 47 Middle East & Africa market share and leading players
  • Fig. 48 North America: SWOT
  • Fig. 49 Europe SWOT
  • Fig. 50 Asia Pacific SWOT
  • Fig. 51 Latin America SWOT
  • Fig. 52 MEA SWOT
  • Fig. 53 North America, by country
  • Fig. 54 North America
  • Fig. 55 North America market estimates and forecasts, 2018 - 2030
  • Fig. 56 U.S.
  • Fig. 57 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 58 Canada
  • Fig. 59 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 60 Mexico
  • Fig. 61 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 62 Europe
  • Fig. 63 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 64 UK
  • Fig. 65 UK market estimates and forecasts, 2018 - 2030
  • Fig. 66 Germany
  • Fig. 67 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 68 France
  • Fig. 69 France market estimates and forecasts, 2018 - 2030
  • Fig. 70 Italy
  • Fig. 71 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 72 Spain
  • Fig. 73 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 74 Denmark
  • Fig. 75 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 76 Sweden
  • Fig. 77 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 78 Norway
  • Fig. 79 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 80 Asia Pacific
  • Fig. 81 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 82 China
  • Fig. 83 China market estimates and forecasts, 2018 - 2030
  • Fig. 84 Japan
  • Fig. 85 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 86 India
  • Fig. 87 India market estimates and forecasts, 2018 - 2030
  • Fig. 88 Thailand
  • Fig. 89 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 90 South Korea
  • Fig. 91 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 92 Australia
  • Fig. 93 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 94 Latin America
  • Fig. 95 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 96 Brazil
  • Fig. 97 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 98 Argentina
  • Fig. 99 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 100 Middle East and Africa
  • Fig. 101 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 102 South Africa
  • Fig. 103 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 104 Saudi Arabia
  • Fig. 105 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 106 UAE
  • Fig. 107 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 108 Kuwait
  • Fig. 109 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 110 Market share of key market players- Alzheimer's disease diagnostics market